# Vaccines Sector Canonical URL: https://biopharmsignal.com/sector/vaccines Vaccines groups companies working on preventive or therapeutic vaccine platforms across infectious disease, oncology, and public health. This sector page includes businesses developing traditional vaccines as well as newer platform approaches such as mRNA or recombinant protein vaccines. Companies currently grouped under Vaccines: 28 ## Recent Sector News - 2026-07-20 10:00 EST — GLSI — [Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4) — Source: Greenwich LifeSciences - 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc - 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc - 2026-07-16 12:31 EST — MRK — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck - 2026-07-16 11:30 EST — GLSI — [Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-popula-adf83f60) — Source: Greenwich LifeSciences - 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc - 2026-07-15 12:31 EST — MRK — [KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy](https://biopharmsignal.com/news/MRK/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-ceac984b) — Source: Merck - 2026-07-15 12:31 EST — MRK — [Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026](https://biopharmsignal.com/news/MRK/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-f70a5c44) — Source: Merck - 2026-07-14 12:00 EST — PMN — [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-5218a89a) — Source: ProMIS Neurosciences - 2026-07-13 12:00 EST — BAVN — [News | Bavarian Nordic](https://biopharmsignal.com/news/BAVN/news-bavarian-nordic-b9e90c06) — Source: Bavarian Nordic - 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc - 2026-07-10 19:01 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-7cdef535) — Source: Merck - 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc - 2026-07-10 10:06 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-bc1625e5) — Source: Merck - 2026-07-10 10:06 EST — MRK — [Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Merck.com](https://biopharmsignal.com/news/MRK/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and--4390af46) — Source: Merck - 2026-07-10 10:06 EST — MRK — [Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Merck.com](https://biopharmsignal.com/news/MRK/merck-to-hold-second-quarter-2026-sales-and-earnings-conference-call-aug-4-merck-44a90bf3) — Source: Merck - 2026-07-09 19:07 EST — MRK — [Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com](https://biopharmsignal.com/news/MRK/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-bb1d1ada) — Source: Merck - 2026-07-09 12:00 EST — NVAX — [Novavax Reports First Quarter 2026 Financial Results and Operational Highlights - May 6, 2026](https://biopharmsignal.com/news/NVAX/novavax-reports-first-quarter-2026-financial-results-and-operational-highlights--a11612f1) — Source: Novavax - 2026-07-09 12:00 EST — NVAX — [Novavax to Participate in BofA Securities 2026 Health Care Conference - May 7, 2026](https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-bofa-securities-2026-health-care-conference-may-7-2026-b9786971) — Source: Novavax - 2026-07-09 12:00 EST — NVAX — [Novavax to Participate in 2026 Jefferies Global Healthcare Conference - Jun 1, 2026](https://biopharmsignal.com/news/NVAX/novavax-to-participate-in-2026-jefferies-global-healthcare-conference-jun-1-2026-13dbcea1) — Source: Novavax ## Companies - [BRNS](https://biopharmsignal.com/company/BRNS) — Barinthus Biotherapeutics - [BAVN](https://biopharmsignal.com/company/BAVN) — Bavarian Nordic - [BLCM](https://biopharmsignal.com/company/BLCM) — Bellicum Pharmaceuticals - [BNTX](https://biopharmsignal.com/company/BNTX) — BioNTech - [CVAC](https://biopharmsignal.com/company/CVAC) — CureVac - [LLY](https://biopharmsignal.com/company/LLY) — Eli Lilly - [GOVX](https://biopharmsignal.com/company/GOVX) — GeoVax Labs - [GRNA](https://biopharmsignal.com/company/GRNA) — GreenLight Biosciences - [GLSI](https://biopharmsignal.com/company/GLSI) — Greenwich LifeSciences - [GSK](https://biopharmsignal.com/company/GSK) — GSK plc - [HLVX](https://biopharmsignal.com/company/HLVX) — HilleVax - [ICVX](https://biopharmsignal.com/company/ICVX) — Icosavax - [INO](https://biopharmsignal.com/company/INO) — Inovio Pharmaceuticals - [MRK](https://biopharmsignal.com/company/MRK) — Merck - [MRNA](https://biopharmsignal.com/company/MRNA) — Moderna, Inc. - [NWBO](https://biopharmsignal.com/company/NWBO) — Northwest Biotherapeutics - [NVAX](https://biopharmsignal.com/company/NVAX) — Novavax - [PDSB](https://biopharmsignal.com/company/PDSB) — PDS Biotechnology Corporation - [PFE](https://biopharmsignal.com/company/PFE) — Pfizer, Inc. - [PMN](https://biopharmsignal.com/company/PMN) — ProMIS Neurosciences - [SNY](https://biopharmsignal.com/company/SNY) — Sanofi - [SELB](https://biopharmsignal.com/company/SELB) — Selecta - [VCNX](https://biopharmsignal.com/company/VCNX) — Vaccinex - [VLA](https://biopharmsignal.com/company/VLA) — Valneva - [VXRT](https://biopharmsignal.com/company/VXRT) — Vaxart - [PCVX](https://biopharmsignal.com/company/PCVX) — Vaxcyte - [VAXX](https://biopharmsignal.com/company/VAXX) — Vaxxinity - [YS](https://biopharmsignal.com/company/YS) — YS Biopharma